Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Dovitinib and Pilot Study of Fibroblast Growth Factor Receptor Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer Previously Treated With Anti-Vascular Endothelial Growth Factor Therapy

Next Previous
X
Search
Trial Profile

Phase II Study of Dovitinib and Pilot Study of Fibroblast Growth Factor Receptor Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer Previously Treated With Anti-Vascular Endothelial Growth Factor Therapy

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dovitinib (Primary)
  • Indications Colorectal cancer; Non-small cell lung cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 23 Jan 2016 Status changed from active, no longer recruiting to discontinued as results presented at the 2016 Gastrointestinal Cancers Symposium
    • 24 Mar 2015 Planned primary completion date changed from 1 Oct 2014 to 1 Oct 2015, according to to ClinicalTrials.gov record.
    • 24 Mar 2015 Status changed from recruiting to active, no longer recruiting, according to to ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top